Hoth Therapeutics, Inc. 8-K

What Happened

• Hoth Therapeutics, Inc. (HOTH) announced in an 8-K (filed April 16, 2026) that it intends to resume selling its common stock under its At-the-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC.
• The company previously suspended use of and terminated the earlier prospectus supplement (reported in an 8-K on April 1, 2026), but the underlying Sales Agreement (dated November 8, 2024) has remained in effect. Hoth will file a new prospectus supplement to its Form S-3 registration statement (File No. 333-291566), which the SEC declared effective on December 4, 2025.
• The legal opinion and consent from Sheppard, Mullin, Richter & Hampton LLP regarding the validity of the securities issued under the Sales Agreement were included.

Key Details

• Sales Agreement counterparty: H.C. Wainwright & Co., LLC (Agreement dated November 8, 2024).
• Registration statement: Form S-3, File No. 333-291566, declared effective December 4, 2025.
• Recent filings: initial suspension/termination of prior prospectus supplement reported April 1, 2026; current 8-K filed April 16, 2026 announcing intent to file a new prospectus supplement.
• Legal counsel: Sheppard, Mullin, Richter & Hampton LLP provided opinion and consent related to the validity of securities.

Why It Matters

• Resuming ATM sales gives Hoth a ready mechanism to raise capital by selling shares into the market over time. That can fund operations, R&D, or other corporate needs without a single large financing event.
• For current and potential investors, ATM sales can lead to dilution as additional shares are sold; the speed and size of any sales depend on the company’s decisions and market demand.
• The filing of a new prospectus supplement and the inclusion of counsel’s opinion are procedural steps required to restart sales under the existing Sales Agreement.